Corrigendum to “PTPN3 is a potential target for a new cancer immunotherapy that has a dual effect of T cell activation and direct cancer inhibition in lung neuroendocrine tumor” [Volume 14, Issue 9, September 2021, 101152] (Translational Oncology (2021) 14(9), (S1936523321001443), (10.1016/j.tranon.2021.101152))

Satoko Koga, Hideya Onishi, Shogo Masuda, Akiko Fujimura, Shu Ichimiya, Kazunori Nakayama, Akira Imaizumi, Kenichi Nishiyama, Masayuki Kojima, Kei Miyoshi, Katsuya Nakamura, Masayo Umebayashi, Takashi Morisaki, Masafumi Nakamurab

研究成果: ジャーナルへの寄稿 › コメント/討論 › 査読

フィンガープリント

「Corrigendum to “PTPN3 is a potential target for a new cancer immunotherapy that has a dual effect of T cell activation and direct cancer inhibition in lung neuroendocrine tumor” [Volume 14, Issue 9, September 2021, 101152] (Translational Oncology (2021) 14(9), (S1936523321001443), (10.1016/j.tranon.2021.101152))」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

Medicine and Dentistry